Treatment effects of intra-articular triamcinolone acetonide in an equine model of recurrent joint inflammation.
Authors: Kearney Clodagh M, Korthagen Nicoline M, Plomp Saskia G M, Labberté Margot C, de Grauw Janny C, van Weeren P R, Brama Pieter A J
Journal: Equine veterinary journal
Summary
# Editorial Summary: Intra-articular Triamcinolone in Recurrent Joint Inflammation Despite widespread clinical use of intra-articular triamcinolone acetonide (TA) for equine joint disease, robust evidence supporting its efficacy remained sparse until this controlled experimental study. Using an eight-horse model where lipopolysaccharide was injected into middle carpal joints across three consecutive cycles two weeks apart, researchers compared TA-treated joints against saline controls, measuring clinical signs and synovial fluid biomarkers (total protein, white blood cell counts, prostaglandins, matrix metalloproteinases, and cartilage breakdown products) over a one-week post-injection window. TA demonstrated genuine anti-inflammatory activity through reduced white blood cell counts and total protein levels persisting to two weeks post-injection, with suppressed matrix metalloproteinase activity evident after the second inflammatory challenge—however, this protective effect failed to sustain beyond four weeks. Notably, the steroid treatment produced paradoxical initial responses, including elevated synovial glycosaminoglycans and prostaglandin E2, suggesting a brief pro-inflammatory phase before the anti-inflammatory action took hold. For practitioners, these findings suggest intra-articular TA offers measurable short-term inflammation control in recurrent joint disease, though the waning effect by four weeks indicates repeat treatment intervals may need reconsideration, and the early elevation in cartilage markers warrants careful clinical monitoring during the immediate post-injection period.
Read the full abstract on PubMed
Practical Takeaways
- •Intra-articular triamcinolone acetonide demonstrates modest anti-inflammatory effects lasting approximately 2 weeks, supporting its use for managing acute joint inflammation but suggesting re-treatment may be needed within this timeframe for ongoing cases
- •The initial elevation in inflammatory markers (GAGs and PGE2) following TA injection indicates a potential short-term inflammatory response that practitioners should monitor for when treating clinical cases
- •This experimental evidence provides some scientific support for the common practice of intra-articular TA injection, though the clinical relevance of specific biomarker changes requires further investigation in naturally-occurring joint disease
Key Findings
- •Triamcinolone acetonide treatment reduced white blood cell counts after first and second inflammation inductions (23.7-35.95 × 10⁹ cells/L lower, P<0.04)
- •TA treatment reduced total protein levels after second induction (7.5 g/L lower, P<0.04) and general MMP activity (51.65 RFU/s lower, P<0.01)
- •Anti-inflammatory effects persisted for up to 2 weeks post-treatment but not at 4 weeks
- •TA treatment paradoxically increased synovial GAG and PGE2 levels after first induction (283.19 µg/mL and 77.80 pg/mL higher respectively, P<0.007), suggesting a potentially detrimental short-term effect